NCT06683755 2024-11-12Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)M.D. Anderson Cancer CenterPhase 1/2 Not yet recruiting30 enrolled